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Abstract  31 
Zolpidem, a GABAA receptor positive modulator, is the gold-standard drug for 32 
treating insomnia. Zolpidem prolongs inhibitory post-synaptic currents to decrease 33 
sleep latency and increase sleep time, effects that depend on α2 and/or α3 subunit-34 
containing receptors. Compared with natural NREM sleep, zolpidem also decreases 35 
the EEG power, an effect that depends on α1 subunit-containing receptors, and 36 
which may make zolpidem–induced sleep less optimal. In this paper we investigate if 37 
zolpidem needs to potentiate only particular GABAergic pathways to induce sleep 38 
without reducing EEG power. Mice with a knock-in F77I mutation in the GABAA 39 
receptor γ2 subunit gene are zolpidem-insensitive. Using these mice GABAA 40 
receptors in the frontal motor neocortex and hypothalamic (tuberomammillary 41 
nucleus) histaminergic-neurons of γ2I77 mice were made selectively sensitive to 42 
zolpidem by genetically swapping the γ2I77 subunits with γ2F77 subunits. When 43 
histamine neurons were made selectively zolpidem sensitive, systemic 44 
administration of zolpidem shortened sleep latency, and increased sleep time. But in 45 
contrast to the effect of zolpidem on wild-type mice, the power in the EEG spectra of 46 
NREM sleep was not decreased, suggesting these EEG power-reducing effects of 47 
zolpidem do not depend on reduced histamine release. Selective potentiation of 48 
GABAA receptors in the frontal cortex by systemic zolpidem administration also 49 
reduced sleep latency, but less so than for histamine neurons. These results could 50 
help with the design of new sedatives that induce a more natural sleep. 51 
  52 
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Significance Statement  53 
Many people who find it hard to get to sleep take sedatives. Zolpidem (Ambien) is the most 54 
widely prescribed “sleeping pill”. It makes the inhibitory neurotransmitter GABA work better 55 
at its receptors throughout the brain. The sleep induced by zolpidem does not resemble 56 
natural sleep because it produces a lower power in the brain waves that occur while we are 57 
sleeping. We show using mouse genetics that zolpidem only needs to work on specific parts 58 
and cell types of the brain, including histamine neurons in the hypothalamus, to induce sleep 59 
but without reducing the power of the sleep. This knowledge could help in the design of 60 
sleeping pills that induce a more natural sleep. 61 
62 
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Introduction  63 
Many healthy people who cannot sleep, as well as many with neurological or mental 64 
illness, take sedatives (Wafford and Ebert, 2008; Winsky-Sommerer, 2009; Nutt and 65 
Stahl, 2010; Mignot, 2013; Rihel and Schier, 2013). Zolpidem (Ambien), a non-66 
benzodiazepine GABAA receptor positive modulator, is currently the most successful 67 
“sleeping-pill” (Nutt and Stahl, 2010). In the US alone there were 53.4 million 68 
prescriptions for zolpidem in 2010 (Greenblatt and Roth, 2012). The drug decreases 69 
sleep latency, the time to the onset of NREM sleep  (Arbilla et al., 1985; Gottesmann 70 
et al., 1998; Alexandre et al., 2008; Anaclet et al., 2012; Xu et al., 2014). After taking 71 
a 10-mg tablet of zolpidem, the average person goes to sleep after about 12 minutes 72 
(Greenblatt and Roth, 2012). Compared with natural (drug-free) NREM sleep, 73 
however, the NREM sleep induced by zolpidem has reduced power in most EEG 74 
frequencies (Landolt et al., 2000; Kopp et al., 2004; Alexandre et al., 2008). This 75 
reduced power may indicate that zolpidem-induced sleep is suboptimal compared 76 
with natural NREM sleep.  77 
 78 
Zolpidem works at three GABAA receptor subtypes: α1βγ2, α2βγ2 and α3βγ2 79 
(Pritchett and Seeburg, 1990; Crestani et al., 2000; Cope et al., 2004; Kopp et al., 80 
2004; Leppa et al., 2011), and has the highest affinity at α1-containing receptors 81 
(Pritchett and Seeburg, 1990). These α1βγ2-containing receptors are expressed 82 
widely (Niddam et al., 1987; Wisden et al., 1988; Pritchett et al., 1989; Wisden et al., 83 
1992; Duncan et al., 1995; Fritschy and Mohler, 1995; Hortnagl et al., 2013). 84 
Surprisingly, the α1-containing GABA receptors are not responsible for zolpidem’s 85 
ability to promote sleep. In mice with α1 subunits made insensitive to zolpidem by a 86 
mutation, H101R, zolpidem reduces latency to NREM sleep and prolongs NREM 87 
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sleep time as well as it does in wild-type mice (Kopp et al., 2004).  Thus, zolpidem’s 88 
sleep-promoting effects come from enhancing GABA’s actions at GABAA receptors 89 
with α2 and/or α3 subunits. Instead, the α1H101R mice do show that α1-containing 90 
receptors are needed for zolpidem to produce its characteristic decrease in the EEG 91 
power in NREM sleep (Kopp et al., 2004). But can zolpidem potentiate α2 and/or α3-92 
containing receptors in only particular GABA pathways to induce sleep without 93 
reducing EEG power? The answer could help design sedatives that produce a more 94 
natural sleep. 95 
 96 
Natural NREM sleep is hypothesized to start when GABA neurons in the preoptic 97 
hypothalamus increase their activity onto, among other targets, the wake-promoting 98 
histaminergic neurons in the tuberomammillary nucleus (TMN) of the posterior 99 
hypothalamus  (Nitz and Siegel, 1996; Sherin et al., 1996; Sherin et al., 1998; Zhang 100 
et al., 2015). Infusing the GABAA agonist muscimol into this area induces sleep (Lin 101 
et al., 1989; Nitz and Siegel, 1996); conversely, injecting GABAA receptor 102 
antagonists there decreases the potency of GABAergic anesthetics (Nelson et al., 103 
2002). Thus GABAA receptor modulators, such as zolpidem, could produce sleep by 104 
decreasing histaminergic activity (Nelson et al., 2002). Histaminergic neurons 105 
express α1β3γ2 and α2β3γ2 GABAA receptors (Fritschy and Mohler, 1995; Sergeeva 106 
et al., 2002; Zecharia et al., 2009; Zecharia et al., 2012; May et al., 2013); and so 107 
GABAA receptors on these neurons could, in part, account either for the EEG power-108 
reducing effect of zolpidem (α1-containing receptors), or critically, the ability of 109 
zolpidem to reduce latency to NREM sleep and increase sleep time (α2-containing 110 
receptors).  111 
 112 
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We previously used a pharmacogenetics method, based on mutated GABAA 113 
receptors, for probing how endogenous GABA inputs onto selected cell types 114 
generates behavior (Wulff et al., 2007; Wisden et al., 2009; Sieghart, 2012). The 115 
mutation F77I in the γ2 subunit (γ2I77) abolishes zolpidem binding to GABAA 116 
receptors (Buhr et al., 1997; Wingrove et al., 1997; Cope et al., 2004). In γ2I77lox 117 
mice the zolpidem-insensitive γ2I77 subunits can be swapped with zolpidem-118 
sensitive γ2F77 versions (Wulff et al., 2007). Here, using this method, we found that 119 
strengthening inhibition onto histamine neurons by zolpidem induces NREM sleep 120 
but does not reduce EEG power.   121 
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MATERIALS & METHODS 122 
Mice. All experiments were performed in accordance with the UK Home Office 123 
Animal Procedures Act (1986); all procedures were approved by the Imperial College 124 
Ethical Review Committee. All mice weighed between 19 and 30 grams and were 125 
approximately 17 weeks old at the time of AAV injections. Both male and female 126 
mice were used, but no sex differences were observed and the data were pooled. 127 
The sleep-wake studies and drug administrations were started about 4 weeks after 128 
AAV injection (see below). Adult C57BL/6J mice were purchased from Harlan (UK). 129 
The HDC-Δγ2I77 mice were produced by crossing HDC-Cre (JAX stock number 130 
021198, RRID:IMSR_JAX:021198) and γ2I77lox (zolpidem-insensitive) mice (JAX stock 131 
number 021197, RRID:IMSR_JAX:021197) on C57BL/6J backgrounds, as described 132 
previously (Zecharia et al., 2012). In adult HDC-Cre mice, Cre recombinase 133 
expression is driven by the endogenous hdc gene and is found selectively in 134 
histaminergic neurons in the TMN, and mast cells in the rest of the brain; the knock-135 
in HDC-Cre allele expresses functional HDC protein (Zecharia et al., 2012). In the 136 
γ2I77lox mice, exon 4 of the GABAA receptor γ2 subunit gene (gabrg2), which 137 
encodes the critical I77 residue, is flanked by loxP sites (Wulff et al., 2007); deletion 138 
of exon 4 by Cre recombinase produces a null gabrg2 allele (Wulff et al., 2007; Wulff 139 
et al., 2009a; Wulff et al., 2009b; Rovo et al., 2014). The baseline vigilance-state 140 
data (% Wake, NREM and REM) recorded for a 2 hour period, as determined by 141 
EEG/EMG scoring, for the mice in drug-free conditions are shown in Table 1 (see 142 
section below, “EEG recordings and sleep scoring”). 143 
 144 
Generation of HDC-γ2F77, FC-γ2F77, and SC-γ2F77 mice. Stereotaxic injections of 145 
AAV were performed with a Leica Angle Two frame under isoflurane anesthesia, 146 
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using Hamilton microliter #701 10-μl syringes with adjoining capillary glass pipettes 147 
tapered 1 mm to ~ 50 μm diameter, back-loaded with mineral oil and AAV mixture 148 
(1:1 with 20% mannitol) in the tip (see section below, “AAV transgenes and AAV 149 
production”). The coordinates of the (bilateral) injection sites according to the digital 150 
atlas of the Leica apparatus were, relative to Bregma: frontal cortex of γ2I77lox mice 151 
(ML ± 1.75, AP 1.87, DV -1.70 (mm), 1.5 μl AAV-Cre-2A-γ2F77 and AAV-flex-rev-152 
EGFP suspension per side, with the two AAVs mixed 1:1 prior to injection); superior 153 
colliculi of γ2I77lox mice (ML ± 1, AP -3.88, DV-2 (mm), 1 μl AAV-Cre-2A-γ2F77 154 
suspension per side); TMN of HDC-Δγ2I77 mice (ML ± 0.92, AP -2.70, DV -5.34 155 
(mm), 1.5 μl AAV- flex-rev-γ2F77-2A-Venus suspension per side). After AAV 156 
injections, the mice recovered for a minimum of four weeks in their home cages. The 157 
baseline vigilance-state data (% Wake, NREM and REM), as determined by 158 
EEG/EMG scoring, for the HDC-γ2F77, FC-γ2F77, and SC-γ2F77 mice in drug-free 159 
conditions for a 2 hour period are shown in Table 1 (see section below, “EEG 160 
recordings and sleep scoring”). 161 
 162 
AAV transgenes and AAV production. The AAV-panpromoter-flex-rev-Venus-2A-163 
γ2F77 transgene was constructed from components of pAAV-CAG-promoter-Cre-2A-164 
γ2F77, kindly provided by Zoltan Nusser, Institute of Experimental Medicine, 165 
Hungarian Academy of Sciences, Budapest, Hungary (Sumegi et al., 2012); and 166 
pAAV-flex-rev-hM4-mCherry (Addgene plasmid 44362, gift of Bryan Roth, University 167 
of North Carolina at Chapel Hill, USA; (Krashes et al., 2011) Addgene, 168 
RRID:SCR_002037). The “panpromoter” in the AAV-panpromoter-flex-rev-γ2F77-2A-169 
Venus  transgene was derived from a fragment of the promoter of the mouse 170 
histidine decarboxylase (hdc) gene; we originally hoped that this hdc promoter 171 
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fragment would be selective for histaminergic cells but found that it worked well in all 172 
neuronal cell types we tested (unpublished). The AAV-panpromoter-flex-rev-γ2F77-173 
2A-Venus transgene plasmid has been deposited at Addgene (Addgene Plasmid 174 
71410, Addgene, RRID:SCR_002037). The AAV-flex-rev-EGFP transgene was 175 
Addgene plasmid 28304 (gift from Edward Boyden, MIT, Cambridge, USA). The AAV 176 
transgenes AAV-flex-rev-γ2F77-2A-Venus, AAV-Cre-2A-γ2F77, AAV-flex-rev-EGFP 177 
were each packaged in AAV1/2 capsids and purified with heparin columns 178 
(Klugmann et al., 2005). AAV was suspended in sterile PBS at 1:1 concentration. 179 
 180 
EEG recordings and sleep scoring. For non-tethered EMG and EEG recordings, 181 
mice were fitted with Neurologger 2A devices (Anisimov et al., 2014). The recordings 182 
took place in home cages. Data were sampled at 200 Hz and downloaded offline and 183 
processed with Spike2 software (Cambridge Electronic Design, Cambridge, UK, 184 
Spike2 Software, RRID:SCR_000903). The EEG was high-pass filtered (0.5 Hz corner 185 
frequency, -3dB). The EMG was band pass filtered (5 – 45 Hz, -3db). Wake, non-186 
REM and REM were first automatically sleep-scored using previously described 187 
criteria (Costa-Miserachs et al., 2003). The EEG results were then manually verified. 188 
To calculate power spectra, segments of NREM identified after sleep scoring were 189 
concatenated and power spectra calculated using a Fast Fourier transform with a 190 
Hanning window function. Segments of data of at least 10 minutes were used. The 191 
power spectra were normalized as we described previously, such that the area under 192 
the saline controls for a given genotype was unity (Zhang et al., 2015). Power 193 
changes were computed as differences in areas under the power spectra.  194 
 195 
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Behavioral experiments and drug administration. Mice were maintained on a 12-hour 196 
light; 12-hour dark cycle with ad libitum food and water. All behavioral experiments 197 
took place during the “lights off” part of the cycle when the mice were most active. In 198 
all cases, we used paired comparisons where the animals served as their own 199 
controls, a within animals approach (cross-over design). The experimenters were not 200 
blinded to treatment. Zolpidem (Tocris Biosciences, UK) was dissolved in equimolar 201 
tartaric acid (BDH Chemicals) in 0.9% w/v saline.  202 
 203 
Immunohistochemistry. Mice were anesthetized with pentobarbital and transcardially 204 
perfused with phosphate-buffered saline followed by 4% paraformaldehyde (PFA). Brains 205 
were submerged in 4% PFA overnight and stored in 30% sucrose. Free floating sections 206 
(40μm) were blocked with 10% normal goat serum, 1% bovine serum albumin, 0.1% Triton X 207 
in PBS (2 hours, room temperature). Sections were incubated for 24-48 hours at 4˚C with 208 
primary antisera: rabbit anti-Cre (1:1000; Novagen, Germany), or rabbit anti-GFP (1:1000; 209 
Stratagene, UK), or rabbit streptavidin (1:1000; Alexofluor 555 conjugate; Life Technologies, 210 
UK). Secondary goat anti-rabbit anti-sera (Alexofluor 488 or 594, 1:1000; Life Technologies, 211 
UK) were incubated for 2 hours at room temperature. Pictures were taken using a Nikon 212 
eclipse 80i microscope with Qcapture Pro software (Q Capture software, 213 
RRID:SCR_014432), or a Zeiss Cell Observer Live Cell Imaging System, or a Zeiss LSM 214 
510 inverted microscope with Zen pro software. Images were processed using ImageJ (open 215 
source, ImageJ, RRID:SCR_003070) and Adobe Photoshop (Adobe Photoshop CS6, 216 
RRID:SCR_014199). 217 
 218 
Quantifying the spread of AAV transduction. For the HDC-γ2F77 mice, Venus-positive 219 
neurons were counted on fixed sections using ImageJ. Signal-emitting outliers (<15μm or 220 
>30μm diameter) were excluded, as were objects visually scored as incorrect, e.g. microglia. 221 
For the FC-γ2F77 and SC-γ2F77 mice, Cre-positive neurons were identified by 222 
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immunohistochemistry and the percentage area of the target region (frontal cortex or 223 
superior colliculi) was calculated, again using ImageJ (ImageJ, RRID:SCR_003070) 224 
. 225 
Brain-slice electrophysiology. We recorded spontaneous IPSCs from whole-cell, 226 
voltage clamped, HDC-neurons of the TMN and pyramidal neurons of the frontal 227 
cortex in acute slices. Brains were rapidly removed and immersed in ice-cold slicing 228 
artificial cerebrospinal fluid (SACSF) (85 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 5 mM 229 
MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, 75 mM sucrose, 11 mM glucose, 230 
bubbled with 95%O2/5%CO2). For the TMN, a tissue block was cut between the 231 
cerebellum and optic tract, and coronal sections were cut to a thickness of 250 μm 232 
on a vibratome. For the frontal cortex, a tissue block was cut between the optic tract 233 
and approximately 1 mm behind the olfactory bulb. After slicing, the holding chamber 234 
was transferred to a 37°C heat block for 15 min and SACSF was gradually 235 
exchanged for recording ACSF (125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM 236 
MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, and 11 mM glucose, pH7.4 bubbled 237 
with 95%O2/5%CO2) over 40 min. Electrophysiological recordings were made at 238 
room temperature. We identified histaminergic neurons by the presence of 239 
hyperpolarization-activated currents (Ih), a transient outward current, and the 240 
spontaneous firing activity of the cells (Stevens et al., 2001). Virally-transduced 241 
pyramidal neurons in the frontal cortex were found by Cre-dependent expression of 242 
EGFP. Pyramidal neurons were identified primarily by morphology. For detection of 243 
IPSCs, we performed whole-cell recordings in voltage-clamp (-60 mV) using internal 244 
pipette solutions containing: 140 mM CsCl, 4 mM NaCl, 0.5 mM CaCl2, 10 mM 245 
HEPES, 5 mM EGTA, and 2 mM Mg-ATP; the pH was adjusted to 7.3 with CsOH.  246 
 247 
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Statistical analysis. For behavioral and EEG comparisons, and comparisons of IPSC 248 
decay times from the electrophysiology analysis, we used two-tailed paired t-tests 249 
(Janusonis, 2009), and normality was assumed. Analyses were performed in 250 
OriginPro 8.6 or GraphPad Prism 4.03 (Graphpad Prism, RRID:SCR_002798). 251 
  252 
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Results 253 
Zolpidem does not induce sleep in γ2I77lox mice 254 
The wild-type γ2 subunit (γ2F77) confers zolpidem sensitivity on α1β, α2β and α3β 255 
subunit-containing GABAA receptors (Pritchett et al., 1989; Pritchett and Seeburg, 256 
1990; Gunther et al., 1995). The binding site for zolpidem, at the interface between 257 
the α and γ2 subunits, requires residue F77 in the γ2 subunit (Buhr et al., 1997; 258 
Wingrove et al., 1997). Changing the F77 residue to I (F77I) abolishes zolpidem 259 
binding. Consequently, knock-in mice with the γ2 point mutation γ2F77I (γ2I77lox 260 
mice) are behaviorally-insensitive to zolpidem in the dose range 1-30 mg/kg (Cope et 261 
al., 2004; Wulff et al., 2007; Leppa et al., 2011). However, EEG and sleep responses 262 
of γ2I77lox mice following zolpidem administration have not been investigated.  263 
C57BL/6J mice and γ2F77lox mice showed no difference in their baseline sleep 264 
parameters (Table 1). We then established how zolpidem (5 mg/kg), compared with 265 
a saline injection, influenced latency to NREM-like sleep and total sleep time in 266 
C57BL/6J mice and γ2F77lox mice.  Zolpidem at 5 mg/kg (systemic injection i.p.) 267 
caused C57Bl/6J (γ2F77) mice to enter NREM sleep in 2.6 ± 0.6 minutes [n = 5; 268 
paired t-test, t (4) = 4.9, p = 0.008] (Fig. 1A), whereas at this dose of zolpidem, 269 
γ2I77lox mice did not fall asleep for 39 ± 7 minutes [n = 6; paired t-test, t (5) = 0.31, p 270 
= 0.77] (Fig. 1B), which was about the same time they and C57BL/6J mice took to 271 
fall into NREM sleep following a saline injection (Fig. 1A). In C57BL/6J mice, in the 272 
first 45 mins post injection, zolpidem more than doubled the amount of NREM-like 273 
sleep over baseline (from 12 ± 1.6 mins to 33 ± 2 mins) [n = 5; paired t-test t (4) = 274 
20.77, p = 0.0003] (Fig. 1C). The effect persisted until at least 90 mins after injection. 275 
These data, reduced sleep latency and prolonged sleep time, are consistent with 276 
previous reports on zolpidem’s action in C57BL/6J mice (Kopp et al., 2004; 277 
 14 
 
Alexandre et al., 2008). By contrast, there was no change in the sleep time above 278 
baseline in zolpidem-injected γ2I77lox mice [n = 6 paired t-test, t (5) = 0.18, p = 0.86] 279 
(Fig. 1D). Examples of the primary EEG/EMG recordings for saline- and zolpidem-280 
injected C57BL/6 (γ2F77) and γ2I77lox mice are shown in Figure 2. 281 
In agreement with previous studies (Kopp et al., 2004; Alexandre et al., 2008), we 282 
found that the power of “NREM sleep” produced by zolpidem in C57BL/6J mice was 283 
lower than that found in natural NREM sleep. Zolpidem reduced power during NREM 284 
sleep (Fig. 3A) over the frequency range between 5 Hz and 16 Hz (n = 5, paired t-285 
test, t(4) = 4.5, p = 0.01).    In γ2I77lox mice, zolpidem injection did not change the 286 
EEG power spectrum in either the waking (Fig. 3B) or NREM (Fig. 3C) states. 287 
 288 
Potentiation of GABA inputs onto histaminergic neurons by zolpidem induces 289 
and maintains NREM sleep  290 
Having demonstrated that γ2I77lox mice do not enter NREM sleep after systemic 291 
zolpidem administration, we next made several areas of the brains of γ2I77lox mice 292 
zolpidem sensitive using the γ2I77 to γ2F77 subunit switch. The first target was 293 
histamine neurons. Previously we generated and studied HDC-Δγ2I77 mice, which 294 
are mice with a deletion of the γ2I77 subunit from histaminergic neurons in the TMN, 295 
obtained by crossing HDC-Cre and γ2I77lox mice (Zecharia et al., 2012). The 296 
histaminergic neurons of these HDC-Δγ2I77 mice lack IPSCs (Zecharia et al., 2012). 297 
Because the HDC-Δγ2I77 mice still had Cre recombinase expressed in their 298 
histaminergic neurons, we could implement a “restorative genetics” strategy and put 299 
the γ2F77 subunit back into the neurons from which the γ2I77 version was deleted. 300 
We introduced the zolpidem-sensitive γ2F77 subunit into the histaminergic neurons 301 
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of HDC-Δγ2I77 mice using a Cre recombinase flex switch-dependent transgene 302 
(Atasoy et al., 2008), flex-rev-γ2F77-2A-Venus, packaged into AAV capsids (Fig. 303 
4A). This AAV-flex-rev-γ2F77-2A-Venus was bilaterally injected into the ventral TMN 304 
area of adult HDC-Δγ2I77 mice to generate HDC-γ2F77 mice (Fig. 4B). The flex 305 
switch in the AAV transgene ensured that γ2F77 expression was restricted to Cre-306 
positive neurons (Fig. 4A). These mice had bilateral expression of the γ2F77-2A-307 
Venus transgene in their TMN area, confined to HDC neurons in the ventral parts of 308 
the TMN (Fig. 4B & C), in an approximately 700μm anterior to posterior segment 309 
(Fig. 4D). The mean number of AAV-transduced neurons in HDC-γ2F77 brains, as 310 
assessed by Venus expression, was compared with a count performed on a brain 311 
from an HDC-Cre x Rosa-YFP reporter mouse cross. We found HDC-Cre x Rosa-312 
YFP mice had about 8000 neurons in which the HDC promoter was active in the 313 
TMN area (data not shown). This could be an overestimate if some of the Rosa-YFP 314 
expression originates from the HDC-Cre gene turning on and off during 315 
development. In the adult HDC-γ2F77 mice, where Venus expression can only be 316 
seen if the HDC-Cre gene is active in the adult, about 7000 Venus-positive cells 317 
could be detected. This number will be an underestimate since it cannot be expected 318 
that all histaminergic neurons in HDC-Δγ2I77 mice would be transduced by the AAV-319 
flex-rev-γ2F77-2A-Venus virus (see below). On the other hand, counts of cells 320 
immunoreactive for histamine estimated that there were 2500-3500 such neurons in 321 
the mouse hypothalamus (Parmentier et al., 2002), and 3800 in the rat determined 322 
by staining with histidine decarboxylase antibodies (Ericson et al., 1987). Given the 323 
difference in sensitivity between the genetic and primary immunoreactive detection 324 
methods, our estimate of histaminergic neuronal number is roughly in the same 325 
range. The extent of AAV transduction in HDC-γ2F77 mice was also ascertained by 326 
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whole-cell voltage-clamp recordings in acute slices made from the posterior 327 
hypothalamus. In the ventral TMN region we found that 10 out of 16 neurons (62.5 328 
%) had restored IPSCs that resembled IPSCs recorded from C57BL/6J neurons (e.g. 329 
Fig. 4E). Of these 16 cells, the remaining 6 still had no IPSCs (not shown). 330 
Presumably these six neurons had not been transduced by AAV-flex-rev-γ2F77-2A-331 
Venus virus and were still HDC-Δγ2I77 knockout cells (Zecharia et al., 2012).  We 332 
confirmed that the HDC-γ2F77 histaminergic neurons with rescued IPSCs also had 333 
restored zolpidem-sensitivity.  Zolpidem (10 μM) applied to C57BL/6 (γ2F77) 334 
histaminergic cells slowed the IPSC decay by 48 ± 8%, from 30 ± 3 ms (control) to 335 
44 ± 3 ms (zolpidem) (n = 5 cells, paired t-test, t (4) = 7.5, p = 0.002; Fig. 4E, left); by 336 
contrast, 10 μM zolpidem applied to γ2I77lox histaminergic neurons had no effect on 337 
the IPSC decay, being  about 23 ± 4 ms (control) and 24 ± 4 ms (zolpidem) (n = 5 338 
cells, paired t-test, t (4) = 0.7, p = 0.27) (Fig. 4E, middle). In contrast, 10 μM 339 
zolpidem applied to HDC-γ2F77 TMN neurons slowed the IPSC decay by about 46 ± 340 
7% from 24 ± 3 ms (control) to about 35 ± 5 ms (zolpidem) (n = 6 cells, paired t-test, 341 
t (5) = 5.7, p = 0.002) (Fig. 4E, right), the same magnitude of response obtained by 342 
applying zolpidem to C57BL/6J histaminergic neurons (Fig. 4E, left). 343 
 344 
The baseline sleep-wake parameters of HDC-γ2F77 mice did not differ from γ2I77lox 345 
or C57BL/6J mice (Table 1). We next examined if administering zolpidem 346 
systemically to HDC-γ2F77 mice induced sleep (Fig. 5). Following a zolpidem (5 347 
mg/kg) i.p. injection, the sleep latency of HDC-γ2F77 mice was significantly 348 
decreased by about 75 ± 6%, from 45 ± 4 minutes (saline) to 11 ± 2 mins (zolpidem) 349 
[n = 4; paired t-test, t (3) = 8, p = 0.004] (Fig. 5A). HDC-γ2F77 mice spent 350 
significantly more time in NREM sleep (21 ± 2 mins) compared with mice injected 351 
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with saline (2.8 ± 1.8 mins) [n = 4; paired t-test, t (3) = 9.5, p = 0.002] (Fig. 5B). 352 
However, in the first 45 mins post-drug injection, zolpidem-injected HDC-γ2F77 mice 353 
slept for about half as much time as zolpidem-injected C57BL/6J mice. Furthermore, 354 
in contrast to zolpidem’s effects in C57BL/6J mice, zolpidem’s ability to prolong sleep 355 
time in HDC-γ2F77 did not persist beyond the first 45 mins post-injection. So we did 356 
not create the full effect of zolpidem (5 mg/kg) in HDC-γ2F77 mice. In the sleep 357 
states induced by zolpidem in the HDC-γ2F77 mice, EEG power in the zolpidem-358 
induced sleep was not significantly reduced compared with that occurring in natural 359 
NREM sleep [n = 4; paired t-test, 2 – 16 Hz inclusive, t (3) = 1.84, p = 0.16] (Fig. 5B, 360 
inset), which contrasts with the effect of zolpidem on EEG power in C57BL/6J mice 361 
(Fig. 3A). Examples of the primary EEG recordings and sleep-scoring for saline- and 362 
zolpidem-injected HDC-γ2F77 mice are shown in Figure 5C. 363 
 364 
The frontal cortex also can contribute to zolpidem-induced sleep induction but 365 
not maintenance.  366 
In some circumstances the frontal cortex could help initiate sleep (see Discussion). 367 
To test if zolpidem might work partly through this route to induce sedation, we made 368 
the frontal cortex of γ2I77lox mice selectively zolpidem-sensitive by genetically 369 
swapping zolpidem-sensitive γ2F77 subunits into γ2I77lox frontal cortical neurons, so 370 
generating FC-γ2F77 mice (Fig. 6A & B). For this, we co-injected bilaterally a mixture 371 
of two AAVs into the frontal cortex, AAV-Cre-2A-γ2F77 and AAV-flex-rev-EGFP. This 372 
produced co-transduced neurons. The swap works as follows. From the AAV-Cre-373 
2A-γ2F77 transgene, the Cre recombinase destroys production of functional γ2I77, 374 
and the zolpidem-sensitive γ2F77 subunit replaces it; the second AAV expresses 375 
EGFP only if Cre recombinase is present, and thus marks neurons that have been 376 
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transduced with AAV-Cre-2A-γ2F77 (Fig. 6A). We visualized the transduced area by 377 
serial sectioning and then immunocytochemistry with GFP antisera (Fig. 6C, 6D). In 378 
all injections, the spread of transduced cells reached rostral almost to the olfactory 379 
bulb and caudal as far as the primary motor cortex (Fig. 6D). AAV-Cre-2A-γ2F77 380 
transgene expression was found in both the frontal motor cortex and the prefrontal 381 
cortical areas (including prelimbic cortex, orbital areas, primary and secondary motor 382 
cortices). Maximally 20% of any given cortical area was transduced, mostly restricted 383 
to the deep layers of cortex, V and VI (Fig. 6C, 6D). To confirm that the γ2I77 to 384 
γ2F77 swap had produced zolpidem-sensitivity in pyramidal neurons of FC-γ2F77 385 
mice, we made acute slices of M1 and M2 frontal neocortex and performed whole-386 
cell voltage-clamp recordings on pyramidal neurons from layers 5 and 6. The 387 
neurons expressing the AAV-Cre-2A-γ2F77 transgene were identified by their 388 
primary EGFP signal. Zolpidem (1 μM) slowed the decay of IPSCs by 63.5 ± 14 % in 389 
EGFP-expressing neurons, from 15.4 ± 1.8 ms (control) to 24.5 ± 2.2 ms (zolpidem) 390 
(n = 6, paired t-test, t (5) = 6.4, p = 0.001) (Fig. 6E, right panel), which was similar to 391 
its effect on the IPSCs of C57BL/6 pyramidal neurons [n = 6, paired t-test, t (5) = 8.8, 392 
p = 0.0003] (Fig. 6E, left panel); by contrast, the decay of IPSCs was unchanged by 393 
zolpidem (13.2 ± 2.2 ms) in γ2I77lox neocortical pyramidal neurons when compared 394 
with control solution (12.8 ± 2.2 ms) [n = 5, paired t-test, t (4) = 1, p = 0.4]  (Fig. 6E, 395 
middle panel). 396 
 397 
The baseline sleep-wake parameters of FC-γ2F77 mice did not differ from γ2I77lox or 398 
C57BL/6J mice (Table 1). We tested if making frontal cortex neurons selectively 399 
zolpidem sensitive was sufficient to produce a behavioral response in FC-γ2F77 400 
mice (Fig. 7). We administered zolpidem (5 mg/kg) to FC-γ2F77 mice, and found that 401 
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this reduced latency to NREM sleep (Fig. 7A). FC-γ2F77 mice had a 50 ± 14 % 402 
shorter latency to NREM sleep (zolpidem: 13 ± 4 mins) compared with those injected 403 
with saline (30 ± 6 minutes) (Fig. 7A) [n = 6; paired t-test, t (5) = 2.6, p = 0.045]. 404 
However, zolpidem did not significantly increase NREM time in FC-γ2F77 mice 405 
compared with those injected with saline [n = 6; paired t-test, t (5) = 1.5, p = 0.2] (Fig. 406 
7B). The EEG power of this sleep following zolpidem administration in FC-γ2F77 407 
mice did not differ from natural NREM sleep [n = 6, paired t-test, 2 – 16 Hz inclusive, 408 
t (5) = 0.95, p = 0.39] (Fig. 7C). Examples of the primary EEG recordings and sleep-409 
scoring for saline- and zolpidem-injected FC-γ2F77 mice are shown in Figure 8. 410 
 411 
The superior colliculi do not contribute to zolpidem’s sleep-inducing actions 412 
Can zolpidem work in any brain area to induce NREM sleep? To test this we looked 413 
at the superior colliculi (Fig. 9). The superior colliculi are not associated with 414 
induction or maintenance of NREM sleep, but do regulate eye movements and visual 415 
attention and also communicate with REM sleep-promoting areas. We made the 416 
superior colliculi (SC) of γ2I77lox mice selectively zolpidem-sensitive. SC-γ2F77 mice 417 
were generated by bilaterally injecting AAV-Cre-2A-γ2F77 into the superior colliculi of 418 
γ2I77lox mice (Fig. 9A, B). AAV-Cre-2A-γ2F77 transgene expression, detected by 419 
staining with Cre recombinase antisera (Fig. 9C), was found throughout the layers of 420 
the superior colliculi. The baseline sleep-wake parameters of SC-γ2F77 mice did not 421 
differ from γ2I77lox or C57BL/6J mice (Table 1). After zolpidem (5 mg/kg) i.p. 422 
injection, the latency to NREM sleep (44 ± 10 mins) of SC-γ2F77 mice did not differ 423 
from that following a saline injection (37 ± 2 mins) (Fig. 9E) [n = 4; paired t-test, t (3) 424 
= 0.8, p = 0.48]. The NREM sleep time of SC-γ2F77 mice was also not increased 425 
during the first 45 minutes after zolpidem administration compared with saline [n = 4; 426 
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paired t-test, t (3) = 0.07, p = 0.95] (Fig. 9F), Zolpidem did not change the proportion 427 
of REM sleep in SC-γ2F77 mice in the first 45 mins after injection.  428 
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Discussion  429 
We have previously suggested that sedatives produce sleep by interacting with the 430 
NREM sleep-inducing circuitry, changing activity in the hypothalamic and brain stem 431 
circuits which globally govern arousal (Nelson et al., 2002; Franks, 2008; Lu et al., 432 
2008; Zhang et al., 2015). We show here that this seems to be the case for zolpidem 433 
too. By using a pharmacogenetic method that probes endogenous GABA tone, we 434 
found that selectively augmenting the active GABA input onto hypothalamic 435 
histamine neurons by systemic zolpidem administration decreased NREM-sleep-436 
latency and enhanced sleep-time but without reducing power in the EEG. As well as 437 
revealing a potential site for zolpidem’s sleep-promoting actions in vivo, our 438 
pharmacogenetic findings support the hypothesis that the initiation of natural NREM 439 
sleep could arise by increased and sustained inhibition onto histaminergic neurons 440 
(Nitz and Siegel, 1996; Sherin et al., 1996; Sherin et al., 1998).  441 
 442 
Clinical features of zolpidem mimicked in mice with brain regions selectively 443 
zolpidem-sensitive 444 
Positive GABAA receptor modulators are often good at inducing sleep (Lancel and 445 
Steiger, 1999; Winsky-Sommerer, 2009; Nutt and Stahl, 2010; Rye et al., 2012). 446 
Zolpidem’s pharmacokinetics make it effective for treating insomnia: it maximally 447 
occupies its receptor sites minutes after entering the blood, causing sleep quickly, 448 
but its short plasma half-life limits “hangovers” (Benavides et al., 1988). In controlled 449 
clinical settings, zolpidem’s main effect on people is to reduce sleep latency; but 450 
overall zolpidem performs no better than placebo in sleep maintenance, wake time 451 
after sleep onset, or number of awakenings (Greenblatt and Roth, 2012). By these 452 
measures, zolpidem’s key clinical action, reduction of sleep latency, is mimicked by 453 
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increasing inhibition onto histaminergic neurons. However, the NREM sleep induced 454 
by zolpidem in humans and wild-type rodents does not entirely resemble natural 455 
sleep because “zolpidem sleep” has diminished power in the EEG compared with 456 
natural NREM sleep for frequencies above 5 Hz in rodents (Kopp et al., 2004; 457 
Alexandre et al., 2008), and most frequencies in humans (Landolt et al., 2000). It is 458 
not clear if this diminished EEG power is a good or bad feature of zolpidem-induced 459 
sleep. But in the HDC-γ2F77 and FC-γ2F77 mice, the power of zolpidem-evoked 460 
NREM sleep was the same as natural NREM sleep, so these “power-decreasing” 461 
effects of zolpidem must originate in other brain areas. This knowledge may be 462 
useful for designing sedatives that produce a more natural sleep. 463 
 464 
Zolpidem can induce NREM sleep by selectively inhibiting histaminergic 465 
neurons 466 
In spite of having a 20-fold higher affinity at α1βγ2-containing GABAA receptors 467 
(Pritchett and Seeburg, 1990), which are the most widely expressed and abundant 468 
type of GABAA receptors in the brain (Pritchett et al., 1989; Wisden et al., 1992; 469 
McKernan and Whiting, 1996), zolpidem (5 mg/kg) induces sleep through the α2βγ2 470 
and/or α3βγ2 GABAA receptors (Kopp et al., 2004).  The α1-containing receptors are, 471 
instead, responsible for the decrease in EEG power across most frequencies greater 472 
than 5 Hz in zolpidem-evoked sleep (Kopp et al., 2004). We might also expect that 473 
zolpidem’s effects, such as sleep, result from additive slowing of IPSCs on cell types 474 
with α2 and/or α3 subunits throughout the brain. But this is not the case. Prolonging 475 
IPSCs on just histaminergic neurons is enough to induce and maintain sleep, 476 
although not to the full extent generated by zolpidem in wild-type C57BL/6J mice. 477 
Zolpidem is probably effective at histamine neurons because of their hub-like nature 478 
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and their  ability to promote arousal and wakefulness (Haas and Panula, 2003). 479 
Although there are relatively few histamine neurons, between 3000-7000 in the 480 
mouse, their axons ascend and descend from the TMN, coursing throughout the 481 
brain, co-releasing histamine and GABA to give balanced arousal (Wada et al., 482 
1991; Haas and Panula, 2003; Yu et al., 2015). Thus acutely inhibiting the “histamine 483 
hub” by zolpidem will cause histamine levels to fall throughout the brain and sleep to 484 
ensue. This fits with previous pharmacological data that infusing GABA agonists into 485 
the TMN area induces sleep (Lin et al., 1989; Nitz and Siegel, 1996), and that 486 
GABA/galanin neurons in the lateral preoptic neurons, which send axons to the 487 
TMN, increase their activity during sleep (Sherin et al., 1996; Sherin et al., 1998). 488 
Histaminergic neurons principally express α1β3γ2 and α2β3γ2 GABAA receptors 489 
(Fritschy and Mohler, 1995; Sergeeva et al., 2002; Zecharia et al., 2009; Zecharia et 490 
al., 2012; May et al., 2013). Thus these α2-containing GABAA receptors on the 491 
histaminergic neurons are likely candidates for a part of zolpidem’s sleep-inducing 492 
actions in vivo. The α1-containing GABAA receptors that cause zolpidem to reduce 493 
EEG power must be on other types of neurons elsewhere. 494 
 495 
Zolpidem can initiate sleep top down from the frontal cortex 496 
We found that zolpidem can act in the frontal neocortex to reduce sleep latency, 497 
although the effect was not as large as for the histaminergic neurons, and sleep time 498 
was also not increased. Other data also link the frontal and prefrontal cortex and 499 
behavioral sleep: sleep can initiate top-down if the frontal cortex is stimulated at 4Hz 500 
(Penaloza-Rojas et al., 1964; Lineberry and Siegel, 1971); slow waves initiate in 501 
frontal neocortex (Massimini et al., 2004; Vyazovskiy et al., 2009); and in human 502 
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aging, atrophy of the medial prefrontal cortex correlates with disrupted NREM slow 503 
waves (Mander et al., 2013).  504 
 505 
Pharmacogenetic manipulation of GABA inputs versus receptor knockouts, 506 
acute versus chronic 507 
There are several caveats to consider when interpreting our results. The first point is 508 
that acute inhibition of one area in the brain could affect circuit dynamics in other 509 
areas (Otchy et al., 2015). The brain’s dense interconnectivity could cloud, rather 510 
than reveal, the function of the inhibited region and so “transient circuit manipulations 511 
may have their own interpretive difficulties”  (Otchy et al., 2015). This could indicate 512 
that zolpidem does not normally induce sleep by enhancing inhibition on histamine 513 
neurons, but only does so in this particular artificial situation whereby the histamine 514 
neurons are made uniquely sensitive to zolpidem in the HDC-γ2F77 mice. The 515 
second point is that different results are often produced by chronic or acute ablations 516 
(Wisden et al., 2009; Otchy et al., 2015).  Genetic ablation of the GABAA receptor γ2 517 
subunit from histaminergic neurons did not affect normal sleep over a 24-hour 518 
period, although it did produce the more subtle effect of preventing the mice settling 519 
down and going to sleep in a new environment – in other words, removing synaptic 520 
GABAA receptors from histaminergic neurons lengthened the latency to NREM sleep 521 
(Zecharia et al., 2012), and this fits with our new data that, going in the opposite 522 
direction, enhancing IPSCs with zolpidem on these neurons shortens the latency to 523 
NREM sleep. Nevertheless, it remains remarkable that fast GABA input to the 524 
histamine neurons is dispensable for controlling the basic sleep-wake cycle. Similar 525 
to our results on histamine neurons, we found that chronic ablation versus acute 526 
pharmacogenetic modulation of GABA inputs on cerebellar Purkinje neurons also 527 
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produced different results: mice with zolpidem-sensitive GABAA receptors selectively 528 
expressed in Purkinje neurons had acute ataxia after being given zolpidem, and so 529 
we concluded that ongoing GABA input onto Purkinje cells modulates motor control 530 
(Wulff et al., 2007; Wisden et al., 2009); by contrast, knocking out the γ2 subunit 531 
selectively and permanently from Purkinje cells, and the consequent removal of fast 532 
synaptic responses to GABA, did not produce overt ataxia, but only a subtle deficit in 533 
limb coordination (Vinueza Veloz et al., 2015). To explain the large difference in 534 
behavioral phenotype produced by acute zolpidem modulation of Purkinje cells and 535 
chronic ablation of fast inhibitory input, we hypothesized that the cerebellar circuitry 536 
with chronically removed synaptic GABA input on Purkinje cells had undergone 537 
adaptation (Wulff et al., 2007; Wisden et al., 2009).  We think the weak phenotypes 538 
produced by γ2 subunit ablation from Purkinje cells and histaminergic cells, and the 539 
contrasting strong phenotypes obtained by acute manipulation with zolpidem are 540 
analogous: the pharmacogenetic “zolpidem method” unmasks the acute role for 541 
GABA in modulating histaminergic neurons, whereas HDC-Δγ2 mice have 542 
undergone compensatory changes. Acute zolpidem manipulation in HDC-γ2F77 543 
mice produces the “true” result.  544 
 545 
Conclusions 546 
Zolpidem has rather subtle effects on synaptic IPSCs. Typically, it prolongs them by 547 
around 50%. We might have expected that zolpidem induces sleep by potentiating 548 
IPSCs everywhere in the brain; the net effect would be behavioral sleep. But instead 549 
we have shown that zolpidem can induce sleep by strengthening GABA signaling on 550 
just one cell type (histamine neurons). Normally, the NREM sleep induced by 551 
zolpidem does not resemble natural sleep - the drug produces a lower power in most 552 
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frequencies of the EEG during NREM sleep. But via histamine neurons, zolpidem 553 
can induce sleep without reducing the EEG power of the sleep. This knowledge 554 
could help design drugs that induce a more natural sleep.  555 
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Figure Legends and Table legend 752 
Table 1. Time in minutes and percentage time spent in Wake, NREM & REM sleep 753 
for the different types of mice used in the study. The data were recorded over a 754 
baseline period of two hours. One-way ANOVA revealed no significant differences 755 
between the mouse types for Wake, NREM or REM sleep. 756 
 757 
Figure 1.  Zolpidem reduces sleep latency and increases sleep time in 758 
C57BL/6J but not in γ2I77lox mice 759 
A, Sleep latencies after saline and zolpidem (5 mg/kg) injections in C57BL/6J and B, 760 
γ2I77lox mice; for C57BL/6J mice, **p = 0.008 (paired t-test); C, time spent in NREM 761 
sleep in the first 45 mins after saline and zolpidem in C57BL/6J and D, γ2I77lox mice. 762 
For C57BL/6J mice, ***p = 0.0003 (paired t-test). 763 
 764 
Figure 2. EEG spectra and sleep scoring for zolpidem-induced sleep in 765 
C57BL/6 (γ2F77) mice compared with γ2I77lox mice. 766 
A, EEG power spectra for C57BL/6J mice injected with saline or 5 mg/kg zolpidem. 767 
The spectra are aligned in register with the theta/delta power ratio, the root mean 768 
square electromyogram (RMS EMG), the primary EEG and the sleep scoring 769 
assignments (wake, NREM, REM). The arrow marks the time of saline or zolpidem 770 
injection. B, EEG power spectra for γ2I77lox mice injected with saline or 5 mg/kg 771 
zolpidem. All alignments of traces are as above in A.  772 
 773 
Figure 3. Zolpidem does not induce sleep in γ2I77lox mice – EEG power 774 
analysis 775 
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A, EEG power spectrum of natural NREM sleep (blue) or zolpidem-induced sleep (5 776 
mg/kg, red) in C57BL/6J(γ2F77) mice. Zolpidem reduced power during NREM sleep 777 
(Fig. 3A) over the frequency range between 5 Hz and 16 Hz (n = 5, paired t-test, t(4) 778 
= 4.5, p = 0.01). B, EEG power spectrum of γ2I77lox mice (n = 6) in the waking state 779 
following saline i.p. injection (black) or zolpidem i.p. (5 mg/kg; red). C, in γ2I77lox 780 
mice, zolpidem does not influence the power spectra during NREM sleep. Typical 781 
epochs of EEG trace are shown. The scale bars in A and C represent 200 μV and 782 
500 ms.  783 
 784 
Figure 4. Making histamine neurons selectively sensitive to zolpidem.   785 
A, Generating the HDC-γ2F77 mice: the alleles HDC-Cre and γ2I77lox in HDC-Δγ2I77 786 
mice, and the AAV flex-switch transgene construct AAV-flex-rev-γ2F77-2A-Venus 787 
used to selectively label (Venus) and introduce zolpidem-sensitivity (γ2F77) in HDC-788 
Δγ2I77 neurons. Open triangles, loxP sites; shaded triangles, lox2272 sites. ITR, 789 
inverted terminal repeats; P, pan-promoter (hdc gene promoter fragment); WPRE, 790 
woodchuck post-transcriptional regulatory element; B, Schematic of AAV 791 
microinjection into the TMN area of HDC-Δγ2 mouse brain. TMN, tuberomammillary 792 
nucleus; C, Histaminergic neurons labelled by Cre-dependent activation of the AAV-793 
flex-rev-γ2F77-2A-Venus transgene, detected by immunocytochemistry with EGFP 794 
antisera; D, Number of Venus-labelled neurons along the rostral-caudal axis of the 795 
posterior hypothalamus, detected by EGFP immunocytochemistry; E, Spontaneous 796 
IPSCs recorded from histaminergic neurons in acute brain slices prepared from the 797 
posterior hypothalamus of C57BL/6J (γ2F77), γ2I77lox and HDC-γ2F77 mice before 798 
(black) and after 10 μM zolpidem (red) application. Traces are peak-normalized, 799 
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superimposed average waveforms. For the C57BL/6J (γ2F77) data, 87 events were 800 
averaged before zolpidem, and 61 events were averaged after zolpidem.  For the 801 
γ2I77lox data, 124 events were averaged before zolpidem and 167 events were 802 
averaged after zolpidem. For the HDC-γ2F77 data, 59 events were averaged before 803 
zolpidem and 90 events averaged after zolpidem. The graphs show the mean 804 
weighted decay times before and after zolpidem application for the different groups 805 
of mice. **p = 0.002 (paired t-test).  806 
 807 
Figure 5.  Selective potentiation of GABA inputs onto histaminergic neurons 808 
allows zolpidem to induce and maintain sleep.   809 
A, Sleep latencies after saline and zolpidem (5 mg/kg) injections in HDC-γ2F77 mice; 810 
**p = 0.004 (paired t-test); B, time spent in NREM sleep in the first 45 mins after 811 
saline and zolpidem in HDC-γ2F77 mice (**p = 0.002); Inset in B, Normalized EEG 812 
power spectra from HDC-γ2F77 mice following zolpidem i.p. (5 mg/kg; red) 813 
compared with their natural NREM sleep spectra (blue).  Typical epochs of EEG 814 
trace are shown. C, EEG power spectra for HDC-γ2F77 mice injected with saline or 5 815 
mg/kg zolpidem. The spectra are aligned in register with the theta/delta power ratio, 816 
the root mean square electromyogram (RMS EMG), the primary EEG and the sleep 817 
scoring assignments (wake, NREM, REM). The arrow marks the time of saline or 818 
zolpidem injection. 819 
 820 
Figure 6. Making frontal cortical neurons selectively sensitive to zolpidem 821 
A, Generating the FC-γ2F77 mice: the γ2I77lox allele and the two AAVs, AAV-Cre-2A-822 
γ2F77 and AAV-flex-rev-EGFP, used to make the zolpidem-insensitive γ2I77 to 823 
zolpidem-sensitive γ2F77 subunit swap in γ2I77lox mice in the frontal cortex; CMV, 824 
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cytomegalovirus enhancer/promoter; ITR, inverted terminal repeats; pA, 825 
polyadenylation signal; WPRE, woodchuck posttranscriptional regulatory element; B, 826 
The two AAVs were mixed and co-injected into the frontal cortex (FC) of γ2I77lox 827 
mice; C, Overall expression of the AAV-Cre-2A-γ2F77 transgene in pyramidal 828 
neurons (e.g. in layer V shown here) was detected by EGFP immunocytochemistry; 829 
D, Percentage area of transduced frontal neocortical sites along the rostral-caudal 830 
axis; E, Peak normalized spontaneous IPSCs recorded from cortical pyramidal 831 
neurons before (black) and after 1 μM zolpidem (red) from C57BL/6J (γ2F77), 832 
γ2I77lox, and FC-γ2F77 neurons. The traces are superimposed averages. To 833 
construct these, 251 events (before zolpidem) and 175 events (after zolpidem) were 834 
averaged for C57BL/6J neurons); 74 events (before zolpidem) and 71 events (after 835 
zolpidem) were averaged for γ2I77lox neurons; 247 events (before zolpidem) and 155 836 
events (after zolpidem) were averaged for HDC-γ2F77 neurons. The graphs show 837 
mean weighted decay times of IPSCs before and after 1 μM zolpidem in C57BL/6J 838 
(γ2F77; ***p = 0.0003, paired t-test), γ2I77lox and FC-γ2F77 (layer 5/6) pyramidal 839 
neurons (***p = 0.001, paired t-test). 840 
 841 
Figure 7. The frontal cortex contributes to zolpidem’s ability to reduce sleep 842 
latency 843 
A, Sleep latencies and B, sleep times in the first 45 mins after either saline or 844 
zolpidem (5 mg/kg) for FC-γ2F77 mice (*p = 0.045, paired t-test). C, Normalized 845 
EEG power spectrum from FC-γ2F77 mice following zolpidem i.p. (5 mg/kg; red) 846 
compared with their natural NREM sleep spectrum (blue).   847 
 848 
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Figure 8.  EEG power spectra and sleep scoring for zolpidem-induced sleep in 849 
FC-γ2F77 mice. 850 
EEG power spectra for FC-γ2F77 mice injected with saline or 5 mg/kg zolpidem. The 851 
spectra are aligned in register with the theta/delta power ratio, the root mean square 852 
electromyogram (RMS EMG), the primary EEG and the sleep scoring assignments 853 
(wake, NREM, REM). The arrow marks the time of saline or zolpidem injection. 854 
 855 
Figure 9. The superior colliculi do not contribute to zolpidem-induced sleep.  856 
A, Generating the SC-γ2F77 mice: the AAV-Cre-2A-γ2F77 transgene used to make 857 
the zolpidem-insensitive γ2I77 to zolpidem-sensitive γ2F77 subunit swap in γ2I77lox 858 
mice; CTX, neocortex; CMV, cytomegalovirus enhancer/promoter; ITR, inverted 859 
terminal repeats; pA, polyadenylation signal; SC, superior colliculi; WPRE, 860 
woodchuck-posttranscriptional-regulatory-element; B, Bilateral AAV-Cre-2A-γ2F77 861 
microinjection into the superior colliculi of γ2I77lox mouse brain to generate SC-γ2F77 862 
mice; C, detection of AAV-Cre-2A-γ2F77 transgene expression in the SC by anti-Cre 863 
immunohistochemistry, SC, superior colliculi; CTX, neocortex; D, Percentage area of 864 
AAV-transduced SC along the rostro-caudal axis, deduced by counting Cre-positive 865 
cells; E, Sleep latency and F,  sleep time after saline and zolpidem (5 mg/kg) 866 
injections in SC-γ2F77 mice.  867 









  1
  Wake  NREM  REM 
Genotype  Mins Percent SEM  Mins Percent SEM  Mins Percent SEM 
C57BL/6J  68.83 57.88 10.38  44.25 37.17 8.00  5.92 4.96 3.01 
γ2I77lox  64.00 54.92 4.68  46.50 39.72 4.47  6.33 5.36 1.74 
HDC-γ2F77  71.58 60.72 5.86  39.08 33.23 5.96  7.08 6.05 1.56 
FC-γ2F77  54.83 47.08 3.48  54.50 46.68 3.50  7.33 6.24 1.38 
SC-γ2F77  64.17 56.12 6.21  46.21 40.45 0.97  3.92 3.43 1.73 
 
Time in minutes spent in Wake, NREM & REM sleep of the different types of mice used in the study. 
